FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992189987> ?p ?o ?g. }

• W1992189987 endingPage "455" @default.
• W1992189987 startingPage "445" @default.
• W1992189987 abstract "Abstract Purpose: BIIB021 is the first oral, synthetic, non-geldanamycin–based HSP90 inhibitor that showed activity in preclinical models at low nanomolar concentrations. We performed a phase 1 trial of BIIB021 administered to subjects with advanced solid tumors. Experimental Design: Sixty patients received BIIB021 capsules orally on days 1, 4, 8, 11, 15, and 18 of each course in schedule 1, and on days 1, 4, 8, 11, 15, 18, 22, and 25 of each course in schedule 2. The treatment schedules were repeated every 28 days. In addition to determining the MTD, we evaluated pharmacokinetics of BIIB021 and pharmacodynamic effects of BIIB021 [Hsp70, HER2 extracellular domain (HER2-ECD)]. Results: The MTD was 700 mg twice weekly when BIIB021 was dosed for 3 weeks out of each 4-week course. The MTD for continuous dosing regimen was established at 600 mg twice weekly. Gastrointestinal (nausea, vomiting), hot flashes, and neurologic (dizziness) events characterize the safety profile of BIIB021 dosed twice weekly, with events mostly mild or moderate. Plasma exposure to BIIB021 was dose-dependent. Cmax occurred at approximately 90 minutes and t1/2 was approximately 1 hour across dosing cohorts of 25 to 800 mg BIIB021 twice weekly. The biologic activity of BIIB021 was demonstrated in serum, PBMCs, and tumor tissue. Hsp70 levels were increased (&gt;150% from baseline) and serum HER2-ECD was significantly decreased (&gt;15% inhibition from baseline). Conclusions: BIIB021 twice weekly, given with or without the 1 of 4-week rest period was tolerated in subjects with advanced solid tumors at doses that are pharmacodynamically active. Clin Cancer Res; 20(2); 445–55. ©2013 AACR." @default.
• W1992189987 created "2016-06-24" @default.
• W1992189987 creator A5010100538 @default.
• W1992189987 creator A5013814515 @default.
• W1992189987 creator A5028833538 @default.
• W1992189987 creator A5032401979 @default.
• W1992189987 creator A5045286901 @default.
• W1992189987 creator A5055424340 @default.
• W1992189987 creator A5080900202 @default.
• W1992189987 creator A5091140864 @default.
• W1992189987 creator A5091434187 @default.
• W1992189987 date "2014-01-15" @default.
• W1992189987 modified "2023-09-25" @default.
• W1992189987 title "A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors" @default.
• W1992189987 cites W1496131048 @default.
• W1992189987 cites W1967438857 @default.
• W1992189987 cites W1975858195 @default.
• W1992189987 cites W1978489370 @default.
• W1992189987 cites W1996807630 @default.
• W1992189987 cites W2006880901 @default.
• W1992189987 cites W2013985798 @default.
• W1992189987 cites W2027145130 @default.
• W1992189987 cites W2037262355 @default.
• W1992189987 cites W2050107769 @default.
• W1992189987 cites W2053503219 @default.
• W1992189987 cites W2070788764 @default.
• W1992189987 cites W2097840941 @default.
• W1992189987 cites W2100214216 @default.
• W1992189987 cites W2108502796 @default.
• W1992189987 cites W2111187586 @default.
• W1992189987 cites W2112417555 @default.
• W1992189987 cites W2114331359 @default.
• W1992189987 cites W2116725504 @default.
• W1992189987 cites W2123895660 @default.
• W1992189987 cites W2132580929 @default.
• W1992189987 cites W2139248078 @default.
• W1992189987 cites W2158341833 @default.
• W1992189987 cites W2165136795 @default.
• W1992189987 cites W2171708713 @default.
• W1992189987 cites W237674313 @default.
• W1992189987 cites W313262789 @default.
• W1992189987 doi "https://doi.org/10.1158/1078-0432.ccr-13-1257" @default.
• W1992189987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24097863" @default.
• W1992189987 hasPublicationYear "2014" @default.
• W1992189987 type Work @default.
• W1992189987 sameAs 1992189987 @default.
• W1992189987 citedByCount "41" @default.
• W1992189987 countsByYear W19921899872014 @default.
• W1992189987 countsByYear W19921899872015 @default.
• W1992189987 countsByYear W19921899872016 @default.
• W1992189987 countsByYear W19921899872017 @default.
• W1992189987 countsByYear W19921899872018 @default.
• W1992189987 countsByYear W19921899872019 @default.
• W1992189987 countsByYear W19921899872020 @default.
• W1992189987 countsByYear W19921899872021 @default.
• W1992189987 countsByYear W19921899872022 @default.
• W1992189987 countsByYear W19921899872023 @default.
• W1992189987 crossrefType "journal-article" @default.
• W1992189987 hasAuthorship W1992189987A5010100538 @default.
• W1992189987 hasAuthorship W1992189987A5013814515 @default.
• W1992189987 hasAuthorship W1992189987A5028833538 @default.
• W1992189987 hasAuthorship W1992189987A5032401979 @default.
• W1992189987 hasAuthorship W1992189987A5045286901 @default.
• W1992189987 hasAuthorship W1992189987A5055424340 @default.
• W1992189987 hasAuthorship W1992189987A5080900202 @default.
• W1992189987 hasAuthorship W1992189987A5091140864 @default.
• W1992189987 hasAuthorship W1992189987A5091434187 @default.
• W1992189987 hasBestOaLocation W19921899872 @default.
• W1992189987 hasConcept C111113717 @default.
• W1992189987 hasConcept C112705442 @default.
• W1992189987 hasConcept C126322002 @default.
• W1992189987 hasConcept C197934379 @default.
• W1992189987 hasConcept C22979827 @default.
• W1992189987 hasConcept C2777288759 @default.
• W1992189987 hasConcept C2780580376 @default.
• W1992189987 hasConcept C2780852908 @default.
• W1992189987 hasConcept C2781413609 @default.
• W1992189987 hasConcept C71924100 @default.
• W1992189987 hasConcept C90924648 @default.
• W1992189987 hasConcept C98274493 @default.
• W1992189987 hasConceptScore W1992189987C111113717 @default.
• W1992189987 hasConceptScore W1992189987C112705442 @default.
• W1992189987 hasConceptScore W1992189987C126322002 @default.
• W1992189987 hasConceptScore W1992189987C197934379 @default.
• W1992189987 hasConceptScore W1992189987C22979827 @default.
• W1992189987 hasConceptScore W1992189987C2777288759 @default.
• W1992189987 hasConceptScore W1992189987C2780580376 @default.
• W1992189987 hasConceptScore W1992189987C2780852908 @default.
• W1992189987 hasConceptScore W1992189987C2781413609 @default.
• W1992189987 hasConceptScore W1992189987C71924100 @default.
• W1992189987 hasConceptScore W1992189987C90924648 @default.
• W1992189987 hasConceptScore W1992189987C98274493 @default.
• W1992189987 hasIssue "2" @default.
• W1992189987 hasLocation W19921899871 @default.
• W1992189987 hasLocation W19921899872 @default.
• W1992189987 hasLocation W19921899873 @default.
• W1992189987 hasLocation W19921899874 @default.
• W1992189987 hasLocation W19921899875 @default.

• next